Coronavirus Vaccine: India's Covid-19 Vaccine, Covaxin is Undergoing trial
The process of preparing indigenous vaccines for the Coronavirus is progressing rapidly in India. India biotech and Zydus Cadila vaccine are undergoing human trials in six cities. On Friday, a 30-year-old man was given 0.5 ml of intramuscular injection of 'Covaxin' prepared by Bharat Biotech in Delhi-based AIIMS. He was the first person from Delhi to be given this injection.
 |
| Coronavirus Vaccine: India's Covid-19 Vaccine, Covaxin is Undergoing trial |
Both Bharat Biotech and Zydus Cadila were allowed the first and second phases of the clinical trial, and on July 15, the first dose of the vaccine was given to Coronavirus candidates.
At the same time, the vaccine prepared by Oxford University will soon be tested in India. Serum Institute, an Indian company working with United Kingdom pharma company AstraZeneca, has said it will begin human trials as soon as it gets regulatory approval.
Bharat Biotech's Covaxin has been developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). The vaccine is being tested in 12 cities, including AIIMS and PGI Rohtak in Delhi and Patna.
The Zydus- produced vaccine (JACOV-D) is currently being tested at its research center in Ahmedabad, but will soon be tested in several cities.
 |
| Coronavirus Vaccine: India's Covid-19 Vaccine, Covaxin is Undergoing trial |
Covaxin trials have begun in Hyderabad, Patna, Kanchipuram, Rohtak and now Delhi, after which the vaccine will be tested in Nagpur, Bhubaneswar, Belgaum, Gorakhpur, Kanpur, Goa and Visakhapatnam.
Dr. Sanjay Rai, the principal investigator of the vaccine testing project at AIIMS, Delhi, said that we (30-year-old man) kept an eye on him for two hours. There were no immediate side-effects. He said that at present he was allowed to go home and he would be examined again after two days.
Human Trial of Corona Vaccine Effective at Oxford University
A human trial at the University of Oxford University in Britain over the Coronavirus vaccine has been effective. Announcing this, the editor-in-chief of The Lancet, a UK-based medical journal, says the vaccine is completely safe, well tolerated and immune. Explain that the British government has tied up with AstraZeneca to get 100 million doses of the vaccine being tested by Oxford University.
AIIMS gives green signal for first human trial of coronavirus vaccine in India
The AIIMS Delhi has been selected by the Indian Council of Medical Research (ICMR) to conduct human trials in steps 1 and 2 of the co-vaccine (Covaxin). AIIMS is also one of the selected 12 sites of ICMR.
The Ethics Committee of AIIMS gave its approval for human trials of the indigenously developed COVID-19 vaccine on Saturday, after which the premier hospital is expected to start the practice by recruiting healthy volunteers from Monday. AIIMS Delhi has been selected by the Indian Council of Medical Research (ICMR) to conduct human trials in steps 1 and 2 of the Covaxin. AIIMS is also one of the selected 12 sites of ICMR. In step 1, the vaccine will be tested on 375 volunteers and maximum of them will be of 100 AIIMS.
 |
| Coronavirus Vaccine: India's Covid-19 Vaccine, Covaxin is Undergoing trial |
Dr. Sanjay Rai, Professor of Center for Community Medicine at AIIMS, said. The AIIMS Ethics Committee today gave its approval to begin human clinical trials of indigenously developed Covaxin. Healthy volunteers who have no history of COVID-19 i.e. they are not suffering from Coronavirus, those who are more than 18 years of age and below 55 years will be eligible to participate in the test.
The lead investigator of the study, Rai, said, "Some volunteers have already registered for the test. We will start screening the individuals and evaluate their health status from Monday before vaccination."
He said that anyone wishing to participate in the trial can send or call on email. The institute can also put these contact details on its website. According to Rai, the Ethics Committee raised some concerns in the protocol presented for carrying out the trial.
The COVID-19 vaccine candidate Covaxin, which was developed by Hyderabad-based Bharat Biotech in collaboration with ICMR and the National Institute of Virology (NIV), recently received approval from the Drone Controller General of India (DCGI) for human clinical trials was.
Noting that it is the first indigenous vaccine developed by India, ICMR Director General Dr. Balaram Bhargava recently said in a letter to the principal investigators of 12 sites that the highest priority projects which are the top-most level of government But they are being monitored and asked to fast track human clinical trials. Testing has so far started in AIIMS, Patna, and a few more sites.
 |
| Coronavirus Vaccine: India's Covid-19 Vaccine, Covaxin is Undergoing trial |
DCGI has allowed two vaccines - one by Bharat Biotech International Limited in collaboration with ICMR and the other by Zydas Cadila Healthcare Ltd to go into step 1 and 2 human clinical trials.
Dr. Balaram Bhargava had said that these two vaccine candidates had conducted successful toxicity studies in mice, and rabbits, and these data were submitted to DCGI, after which both were to begin early stage human trials earlier this month Got approval
He said his site was ready and about 1,000 human volunteers would participate in the practice for each of the indigenously developed vaccine candidates. Since India is one of the world's largest vaccine producers, it is the country's "moral responsibility" to fast-track the vaccine development process to break the chain of Coronovirus transmission.
Coronavirus Vaccine UK Oxford AstraZeneca
Researchers at the University of Oxford have revealed that they may be successful in their effort to produce the COVID-19 vaccine. The University of Oxford team has announced after discovering that the Jab may provide "dual protection" against lethal Coronaviruses after early-stage human trials. Human trials from Oxford-AstraZeneca showed that vaccine supplements successfully managed to produce both antibodies and "killer T-cells" in the receiver's body. The results are promising because individual studies have indicated that antibodies can go away for months while T-cells can remain in circulation for years.
The University of Oxford is developing a potential Coronavirus vaccine candidate ChAdOx1 nCoV-19, in collaboration with global biopharmaceutical firm AstraZeneca. The vaccine candidate has entered a third stage human trial. While a Phase 1 trial of a potential Coronavirus vaccine has shown promising results, complete data will be published on July 20.
Coronavirus vaccine Russia
Russia has said that its "world's first Coronavirus Covid 19 vaccine" is 'safe'. The Defense Ministry of that country has revealed that all volunteers who were part of human trials did not show "serious adverse events, health complaints, complications or side effects". The Ministry of Defense has revealed that it hopes to have clinical trials of a potential coronavirus vaccine in place by the end of July. Moscow officials had previously said that "civil distribution" of the Coronavirus vaccine could begin in mid-August and mass production in September. Russia plans to produce 30 million doses of the potential COVID-19 vaccine in 2020, with the potential to manufacture another 170 million overseas, according to Reuters reports.
Coronavirus Vaccine USA Moderna
US-based Modern Kaiser Permanente is working on a potential Coronavirus vaccine candidate known as mRNA-1273 in collaboration with the Washington Health Research Institute. Modern's first phase began on March 16 and Morden was the first organization to begin clinical trials of a potential Coronavirus vaccine candidate. An interim analysis showed that according to a report published in the New England Journal of Medicine, an immune response arose in participants of Phase I clinical trials. Modern will begin its Phase III trial on July 27.
 |
| Coronavirus Vaccine: India's Covid-19 Vaccine, Covaxin is Undergoing trial |
COVID coronavirus vaccine WHO
The World Health Organization (WHO) has revealed that more than 150 potential vaccines of Coronavirus are in various stages of development. Therefore, about 23 vaccines have managed to reach the stage of human trials. Meanwhile, the heads of state of eight countries - Canada, Tunisia, Spain, New Zealand, South Korea, Ethiopia, Sweden, and South Africa - have demanded fair distribution of the Coronavirus vaccine as it develops.
Comments
Post a Comment
If you have any query please let me know